ip6k1

TNP (IP3K Inhibitor) is a cell-permeable inhibitor of IP6K1 and IP3K, with IC 50 values of 0.55 μM and 10.2 μM for IP6K1 and IP3K, respectively. TNP binds to the ATP-binding sites of both enzymes [1].

LI-2242 is a potent inositol hexakisphosphate kinase (IP6K) inhibitor with IC50s of 31 nM, 42 nM, 8.7 nM, and 1944 nM for IP6K1, IP6K2, IP6K3, and IPMK, respectively.LI-2242 ameliorated hepatic steatosis by reducing the expression of genes that enhance lipid uptake, lipid stabilization, and adipogenesis, and enhanced mitochondrial oxygen consumption rate (OCR) and insulin signaling in adipocytes and hepatocytes in vitro. LI-2242 ameliorated diet-induced obesity, hyperglycemia and hepatic steatosis in mice.LI-2242 can be used to study type II diabetes, obesity, metabolic complications, venous thrombosis and psychiatric disorders.

IP6K2-IN-2 is an IP6K2 inhibitor with IC₅₀ values of 0.58 μM, 0.86 μM, and 3.08 μM for IP6K2, IP6K1, and IP6K3, respectively. It can be used in obesity research.

SC-919 (LI-2124) is an orally active and selective inhibitor that targets inositol hexakisphosphate kinases (IP6K, including the subtypes IP6K1, IP6K2, and IP6K3), with an IC50 value of 0.65 nM for IP6K3. By inhibiting IP6K, SC-919 reduces the production of inositol pyrophosphates (such as InsP₇), thereby inhibiting XPR1-mediated phosphate efflux from cells and increasing intracellular ATP levels. SC-919 shows potential for research in hyperphosphatemia associated with chronic kidney disease (CKD).

UNC7467 is a potent IP6K inhibitor with IC50 values of 4.9 nM for IP6K2, 8.9 nM for IP6K1, and 1320 nM for IP6K6. It effectively reduces inositol pyrophosphate levels without significantly affecting other inositol phosphates and is applicable for obesity research [1].

TBK1/IKKε-IN-3, a potent IP6K inhibitor, exhibits IC50 values of 3, 8.65, and 3.72 μM for IP6K1, IP6K2, and IP6K3, respectively. It is applicable in obesity disease research. [1]